申请人:USV PHARMACEUTICAL CORPORATION
公开号:EP0039804A1
公开(公告)日:1981-11-18
wherein:
R1, R2, R3 and R4 are each hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl, polycycloalkyl, or heterocycloalkyl;
n is an integer from 0 to 4 inclusive;
Rs is hydrogen, alkyl, aralkyl, aryl, hydroxyalkyl, aminoalkyl, alkanoyl, aryloyl, arylalkanoyl, hydroxyalkanoyl, carboxyalkanoyl, aminoalkanoyl, cyano, amino, alkylamino, arylamino, amidino, alkylamidino, arylamidino, or ZS-, ZS(CR1R2)n- or ZSCO- wherein Z is alkyl, aryl, aralkyl or a radical of the formula
wherein R1, R2, R3, R4, Re, R7, n, X1, X2 and Y are as herein defined;
Y is OH, OM, OR1. NR1R2, or -NR1-(CR1R2)n-CO-Y' wherein M is a pharmaceutically acceptable cation, R1, R2 and n are as herein defined, and Y, is OH, OM, OR1 or NR1R2;
X, and X2 are each S, SO, -S02, NR1, a chemical bond, 0, (CR8R9)m, CHOH, or -CRe =CR9-, with the proviso that at least one of X1 and X2 be (CR8R9)m, wherein Re and R9 are independently hydrogen or lower alkyl, and m is an integer from 0 to 5;
Ar is a divalent arylene or heteroarylene; and
R6 and R7 are each hydrogen, alkyl, halo, cyano, hydroxy, alkoxy, amino, alkylamino, dialkylamino, mercapto, alkylmercapto, nitro, trifluoromethyl, carboxy, carbalkoxy, COY, or NHCONHR1, wherein R, and Y are as herein defined.
其中:
R1、R2、R3 和 R4 各为氢、烷基、烯基、炔基、芳基、杂芳基、芳烷基、杂烷基、环烷基、多环烷基或杂环烷基;
n 是 0 至 4(包括 4)的整数;
Rs 是氢、烷基、芳烷基、芳基、羟基烷基、氨基烷基、烷酰基、芳基、芳基烷酰基、羟基烷酰基、羧基烷酰基、氨基烷酰基、氰基、氨基、烷基氨基、芳基氨基、脒基、烷基脒基、芳基脒基,或 ZS-、ZS(CR1R2)n- 或 ZSCO-,其中 Z 是烷基、芳基、芳烷基或式中的自由基。
其中 R1、R2、R3、R4、Re、R7、n、X1、X2 和 Y 如本文所定义;
Y 是 OH、OM、OR1.NR1R2,或-NR1-(CR1R2)n-CO-Y',其中 M 是药学上可接受的阳离子,R1、R2 和 n 如本文所定义,Y 是 OH、OM、OR1 或 NR1R2;
X和X2各自为S、SO、-S02、NR1、化学键、0、(CR8R9)m、CHOH或-CRe =CR9-,但X1和X2中至少有一个为(CR8R9)m,其中Re和R9独立地为氢或低级烷基,m为0至5的整数;
Ar 是二价芳基或杂芳基;以及
R6 和 R7 各自为氢、烷基、卤代、氰基、羟基、烷氧基、氨基、烷基氨基、二烷基氨基、巯基、烷基巯基、硝基、三氟甲基、羧基、碳烷氧基、COY 或 NHCONHR1,其中 R 和 Y 如本文所定义。